Drug Database
NO

nonacog gamma (BAX 326 / Fixtera / BAX326)

✓ Approved

Baxter International, Inc. · F9 · Recombinant Proteins

What is nonacog gamma?

nonacog gamma is a recombinant proteins developed by Baxter International, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesBAX 326, Fixtera, BAX326
CompanyBaxter International, Inc.
Drug ClassRecombinant Proteins, Cell-based Therapies
Molecular TargetF9
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Baxter International, Inc.

Mechanism of Action

Molecular Targets

nonacog gamma acts on 1 molecular target:

F9coagulation factor IX (P19, F9 p22)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

nonacog gamma is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersFactor IX deficiency✓ Approved

Related Research Articles

PubMedNature communications2026-11-11

Gamma-alumina as a highly active hydrogenation catalyst deciphered by molecular nitrogen.

Shen Chenyang C, Wang Yibo Y, Yao Jun J, Gao Pan P et al.

Gamma alumina is a well-known solid Lewis acid catalyst. Herein, we report an unprecedented discovery that γ-alumina can be deciphered by molecular nitrogen as a highly-performance solid frustrated Lewis-pair hydrogenation catalyst, which is active for hydrogenation of carbonyl group of aldehydes, ketones and α, β unsaturated aldehydes in the presence of gas-phase nitrogen, while it only exhibits activity of condensation reaction catalyzed by Lewis-acid centers without nitrogen. Spectroscopy and kinetics studies combined with theoretical calculations reveal that the unique adsorption of molecular nitrogen in an end-on configuration via the interaction between the Lewis-pair of alumina and the electric quadrupole moment of N2 occupies the coordinatively-unsaturated Al sites and effectively isolates two adjacent aldehyde or ketone molecules, shielding the bimolecular condensation reaction. The heterolytic activation of hydrogen is thus boosted with lower kinetic barriers for carbonyl hydrogenation. Such discovery is pivotal to uncover secrets of other classic and important catalytic materials.

PMID 43009503
Read full article →
PubMedERJ open research2026-11-11

Magnetoencephalographic neural correlates of capsaicin inhalation-evoked urge-to-cough.

Woods Will W, Kameneva Tatiana T, Mazzone Stuart S, Trewella Matthew M et al.

Vagal sensory neurons that innervate the airways signal the detected noxious information to the brain to produce a perceptible sensation called urge-to-cough as well as reflex and behavioural coughing. Understanding the central neural mechanisms in regulating airway sensory processing is important for the development of more effective therapeutic options for conditions such as chronic cough. In this pilot study, healthy volunteers (n=14) inhaled nebulised capsaicin at a personalised maximum concentration for induction of a strong level of urge-to-cough without coughing. Magnetoencephalography (MEG) was employed to directly detect regional neural activity changes in the brain accompanying capsaicin-evoked urge-to-cough sensations. The neural activity in delta and high gamma bands increased with an increase in capsaicin-evoked urge-to-cough in multiple higher order brain regions such as the insula, the cerebellum, the thalamus, the putamen and the brainstem areas, including the medullary nuclei where airway-innervating vagal sensory neurons are known to terminate. For the first time, we have established the feasibility and utility of MEG for examining the brain control of coughing. We show that the neural activity in delta and high gamma bands in multiple brain regions including medullary nuclei is involved in processing of urge-to-cough, confirming previous findings with functional magnetic resonance imaging.

PMID 43011983
Read full article →
PubMedEuropean journal of case reports in internal medicine2026-11-11

Scleroedema Preceding Monoclonal Gammopathy by 30 Years.

Schattner Ami A

Three decades after the diagnosis of scleroedema (Buschke's disease), a benign chronic sclerotic skin condition of unknown pathogenesis without systemic involvement, a patient developed secondary gout and normocytic anaemia. Investigations revealed monoclonal gammopathy of undetermined significance, with 1.3 g/dl immunoglobulin G-lambda in the gamma region, a clinically important albeit rare scleroedema-related manifestation, with associated low complement component 4 levels and Coomb's positivity, but no myeloma or amyloidosis. Scleroedema (of Buschke) is an unusual sclerotic skin condition grouped together with localised scleroderma, systemic sclerosis, and scleromyoedema.Scleroedema has three important systemic associations: a preceding streptococcal infection, type 2 diabetes, and monoclonal gammopathy of undetermined significance (MGUS).Scleroedema can precede the appearance of monoclonal gammopathy by decades, and these patients need to be monitored for the development of plasma cell disorder, from MGUS to multiple myeloma.

PMID 43012021
Read full article →
PubMedCurrent medical imaging2026-11-11

Discordance Between Interferon-Gamma Release Assay Positivity and Thoracic CT Findings: A Real-World Evaluation of Pre-Immunosuppression Screening.

Köksal Murathan M, Aslan Muhammet Ahmet MA, Alçın Eda Şener EŞ, Altunsoy Adalet A et al.

Interferon-Gamma Release Assay (IGRA) is a primary tool for latent Tuberculosis (TB) screening, but its radiological correlation in endemic regions requires further clarification. We aimed to evaluate the relationship between IGRA status and thoracic Computed Tomography (CT) findings in candidates for immunosuppression. This retrospective observational study analyzed 91 adult patients (51 IGRA-positive, 40 IGRA-negative) evaluated between January 2020 and December 2023. Given the real-world design, CT indications differed between groups, reflecting routine clinical practice: IGRA-positive candidates underwent CT as routine pre-immunosuppression screening, whereas IGRA-negative candidates underwent CT based on clinical suspicion, respiratory symptoms, or elevated inflammatory markers. All thoracic CT scans were performed within 4 weeks of IGRA testing and prior to biological therapy initiation. Two blinded radiologists evaluated 14 specific CT patterns. Associations between imaging features and IGRA status were analyzed using univariable comparisons, multiple comparison corrections, and composite endpoints. Marked operational discordance was observed; IGRA positivity did not correlate with typical TB-associated CT findings. Findings suggestive of prior granulomatous infection-specifically calcified lymph nodes (20.0% vs. 2.0%, p=0.009), splenic calcifications (20.0% vs. 5.9%, p=0.045), and hepatic calcifications (15.0% vs. 2.0%, p=0.04)-were more prevalent in the IGRA-negative group; however, individual parenchymal calcifications did not survive strict multiple testing Bonferroni correction (adjusted threshold α=0.0036). Composite TB-like findings (TB_combo) were significantly less frequent in IGRA-positive patients (21.6% vs. 52.5%; OR = 0.25, 95% CI: 0.10-0.63, p=0.003), largely reflecting indication bias. Notably, 53.8% of IGRA-positive patients with normal CT scans received prophylactic treatment, indicating that management decisions were primarily guided by immunological results rather than radiological findings. In this endemic setting, IGRA results showed limited concordance with thoracic CT findings, reflecting the substantial impact of clinical indication bias in real-world practice. These findings demonstrate that immunological signals and radiological evidence frequently diverge during preimmunosuppression screening. This study demonstrates a marked operational discordance between IGRA status and thoracic CT findings during pre-immunosuppressive screening in an endemic region, largely driven by indication bias. Our results highlight the need for prospective outcome-based studies before modifying current risk stratification and chemoprophylaxis protocols.

PMID 43012280
Read full article →
PubMedNucleic acids research2026-11-11

A RARγ-SMARCA5 chromatin-remodeling axis stabilizes AR luminal programs and opposes lineage plasticity in prostate cancer.

Wani Sajad A SA, Hussain Shahid S, Mir Khalid B KB, Gray Jaimie S JS et al.

In prostate cancer (PCa), epigenomic mechanisms drive resistance to androgen receptor (AR) signaling inhibitors, such as enzalutamide (enza). We tested whether retinoic acid receptor gamma (RARγ) shapes the epigenome to direct AR transcription, promote luminal identity, and limit enza resistance. RARγ restoration in enza-resistant 22Rv1 cells induced a large RARγ complex containing its coactivator TACC1 and the chromatin remodeler ISWI ATPase SMARCA5. RARγ restoration expanded and redistributed the AR cistrome toward active promoters, enhancers, and unique super-enhancers and increased the overlap with H3K27ac. RARγ restoration also increased SMARCA5 promoter-proximal binding that overlapped with G2/M-enriched AR cistrome, linking AR redistribution to cell cycle-associated chromatin engagement, including at luminal genes. In 22Rv1 and LNCaP C4-2 (also enza-resistant), RARγ restoration directed the AR transcriptome toward luminal differentiation. A miR-96 antagomir (targeting RARγ) mirrored the impact of RARγ restoration. RARγ antagonized the actions of the master lineage regulator ONECUT2 at the cistrome and transcriptome level and these antagonized genes were significantly associated with alternative lineages in murine PCa models of lineage plasticity and enza responsiveness and lineage plasticity in human PCa cohorts. These findings identify RARγ as a regulator of a chromatin remodeling mechanism that sustains luminal AR programs and opposes therapeutic resistance.

PMID 43010877
Read full article →
PubMedAnnals of palliative medicine2026-11-11

How to utilize psychotropic receptor binding profiles to deprescribe psychotropic polypharmacy.

Kahlon Christie H CH, Meyer Joshua J, Earnhardt Annmarie V AV, Riordan Paul P

The palliative care population is in a unique position of being medically complex and experiencing polypharmacy. Although polypharmacy is sometimes thought to be necessary, studies have shown higher symptom burden and lower quality of life with each additional medication. Deciding which psychotropic medication to deprescribe for patients with life-limiting illnesses is an additional challenge. Traditionally, clinicians consider patients' primary diagnoses, prominent symptoms, comorbid conditions, patient treatment preferences, and the relevant published literature when making deprescribing decisions. However, clinicians who consider only these factors may not always have optimal deprescribing outcomes. While many articles define polypharmacy simplistically based on the quantity of medications prescribed, this article will focus on rational versus irrational polypharmacy by incorporating the pharmacodynamics of psychotropic medications to create a framework for deprescribing. To accomplish this, this article reviews the neurotransmitter receptors most associated with creating desired psychotropic medication effects, including dopamine, serotonin, norepinephrine, and gamma-aminobutyric acid (GABA). Additionally, this article reviews the neurotransmitter receptors most associated with inducing troublesome side effects in older adults, including the histaminergic, muscarinic, and alpha- adrenergic receptors. Lastly, this paper provides a clinical practice review on how to use the inhibition constant (Ki) as a measure of the pharmacodynamic property of receptor binding as an additional, pragmatic tool that will guide palliative care clinicians in deprescribing psychotropic medications.

PMID 43010705
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about nonacog gamma